A significant breakthrough in HIV treatment offers a new path forward for thousands of patients who struggle with daily medication adherence. Recent results from the LATITUDE trial demonstrate that monthly injections of cabotegravir and rilpivirine are significantly more effective at maintaining viral suppression than traditional daily oral pills.
For many patients, the requirement to take medication at the same time every day presents a major hurdle. The trial focused on individuals who had previously stopped treatment or struggled to keep their viral loads at undetectable levels. When these patients switched to the monthly injectable regimen, failure rates dropped to 22.8 percent compared to 41.2 percent in the group that continued with daily pills.
In Kenya, approximately 126,000 people living with HIV are on treatment but have not achieved viral suppression. While the national program has made massive strides toward the UNAIDS targets, this group remains at risk of viral rebound and drug resistance. The injectable treatment simplifies the process by removing the need for daily decisions, shifting the responsibility to a monthly clinical appointment.
The findings from the LATITUDE trial suggest that changing how care is delivered is essential to reaching the final gaps in treatment coverage. With the evidence now public, the focus shifts to regulatory approval and health system implementation. Ensuring these treatments reach the patients who need them most is a critical step toward the 2030 goal of ending the epidemic.